We manufacturer the patented Doppler Carotid Shunts for use in Hospitals in the USA. The Doppler provides audible verification of blood flow through the shunt. Some complications unintentionally occur during a shunt being used and our Doppler makes shunts
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.